Everstar Medicines (Shanghai) Limited

To evaluate the pharmacokinetic characteristics of budesonide after a single dose of Nefecon in healthy Chinese volunteers and to evaluate the safety and tolerability of Nefecon in healthy Chinese volunteers.

Primary objective: To evaluate the plasma pharmacokinetics (PK) of ralinepag in healthy Chinese subjects after a single oral administration of 50, 100, and 150 μg ralinepag extended-release (XR) tablets (50 μg extended-release tablets) Secondary objective: To evaluate the safety and tolerability of ralinepag in healthy Chinese subjects after a single oral dose

To evaluate the efficacy, safety, and tolerability of Nefecon 16 mg/day in patients with primary IgAN at risk of progression to end-stage renal disease (ESRD) on top of maximally tolerated therapy with renin-angiotensin system (RAS) blockade based on angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).